XBI vs. ARKK
Compare and contrast key facts about SPDR S&P Biotech ETF (XBI) and ARK Innovation ETF (ARKK).
XBI and ARKK are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. ARKK is an actively managed fund by ARK. It was launched on Oct 31, 2014.
Performance
XBI vs. ARKK - Performance Comparison
Loading graphics...
XBI vs. ARKK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 4.76% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
ARKK ARK Innovation ETF | -12.13% | 35.49% | 8.40% | 69.04% | -66.97% | -23.60% | 152.71% | 35.08% | 3.52% | 87.33% |
Returns By Period
In the year-to-date period, XBI achieves a 4.76% return, which is significantly higher than ARKK's -12.13% return. Over the past 10 years, XBI has underperformed ARKK with an annualized return of 9.32%, while ARKK has yielded a comparatively higher 14.34% annualized return.
XBI
- 1D
- 7.53%
- 1M
- 0.28%
- YTD
- 4.76%
- 6M
- 27.90%
- 1Y
- 58.08%
- 3Y*
- 19.00%
- 5Y*
- -1.29%
- 10Y*
- 9.32%
ARKK
- 1D
- 6.41%
- 1M
- -7.30%
- YTD
- -12.13%
- 6M
- -21.68%
- 1Y
- 42.06%
- 3Y*
- 19.10%
- 5Y*
- -10.73%
- 10Y*
- 14.34%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XBI vs. ARKK - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than ARKK's 0.75% expense ratio.
Return for Risk
XBI vs. ARKK — Risk / Return Rank
XBI
ARKK
XBI vs. ARKK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and ARK Innovation ETF (ARKK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XBI | ARKK | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.02 | 0.99 | +1.02 |
Sortino ratioReturn per unit of downside risk | 2.70 | 1.63 | +1.07 |
Omega ratioGain probability vs. loss probability | 1.34 | 1.19 | +0.15 |
Calmar ratioReturn relative to maximum drawdown | 3.72 | 1.24 | +2.49 |
Martin ratioReturn relative to average drawdown | 13.98 | 3.22 | +10.76 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| XBI | ARKK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.02 | 0.99 | +1.02 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.04 | -0.23 | +0.19 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.29 | 0.36 | -0.07 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.36 | 0.32 | +0.04 |
Correlation
The correlation between XBI and ARKK is 0.70, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
XBI vs. ARKK - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.34%, while ARKK has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
ARKK ARK Innovation ETF | 0.00% | 0.00% | 0.00% | 0.70% | 0.00% | 0.55% | 1.64% | 0.38% | 3.14% | 1.32% | 0.00% | 2.27% |
Drawdowns
XBI vs. ARKK - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, smaller than the maximum ARKK drawdown of -80.97%. Use the drawdown chart below to compare losses from any high point for XBI and ARKK.
Loading graphics...
Drawdown Indicators
| XBI | ARKK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.89% | -80.97% | +17.08% |
Max Drawdown (1Y)Largest decline over 1 year | -13.39% | -31.35% | +17.96% |
Max Drawdown (5Y)Largest decline over 5 years | -55.04% | -77.23% | +22.19% |
Max Drawdown (10Y)Largest decline over 10 years | -63.89% | -80.97% | +17.08% |
Current DrawdownCurrent decline from peak | -26.17% | -56.23% | +30.06% |
Average DrawdownAverage peak-to-trough decline | -20.91% | -29.80% | +8.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.71% | 12.05% | -8.34% |
Volatility
XBI vs. ARKK - Volatility Comparison
The current volatility for SPDR S&P Biotech ETF (XBI) is 11.60%, while ARK Innovation ETF (ARKK) has a volatility of 12.71%. This indicates that XBI experiences smaller price fluctuations and is considered to be less risky than ARKK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| XBI | ARKK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.60% | 12.71% | -1.11% |
Volatility (6M)Calculated over the trailing 6-month period | 19.25% | 27.59% | -8.34% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.24% | 42.61% | -13.37% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.23% | 46.38% | -14.15% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.15% | 40.12% | -7.97% |